Saiseikai Maebashi Hospital

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia1 trial
• Fatty liver disease (MASLD/MASH)1 trial

Phase

• Phase 32 trials

Status

• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Daiichi Sankyo1 trial
• Eli Lilly and Company1 trial

Running trials

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Takeshi Hatanaka (principal investigator)

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting